CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made cancer vaccine shows promise in early trial
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study tests a personalized vaccine made from unique markers on a patient's own tumor. The goal is to help the immune system fight advanced breast cancer, melanoma, and lung cancer that has not responded to other treatments. About 25 adults with these cancers will…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 29, 2026 15:02 UTC
-
New combo therapy aims to outsmart Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two drugs—cabozantinib and nivolumab—in people with advanced melanoma or head and neck cancer that has stopped responding to immunotherapy. The goal is to see if the combination can shrink or stabilize tumors, and whether certain biological markers in the tumor c…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system attack cancer more effectively. …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
New drug combo trial aims to tame advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IACS-6274, alone or with other medicines, in people with advanced solid tumors (like melanoma, ovarian, or head and neck cancers) that have not responded to standard treatments. The main goal is to find the safest dose and understand…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
New hope for melanoma brain metastases: which drug combo works best?
Disease control Recruiting nowThis study tests two different drug combinations in people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib + binimetinib) plus an immunotherapy (nivolumab). The other gets two immunotherapies (ipilimumab + nivolumab). Th…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Could the time of day you get immunotherapy change your outcome?
Symptom relief Recruiting nowThis study looks at whether giving two immunotherapy drugs (ipilimumab and nivolumab) in the morning helps people with advanced melanoma live longer without their cancer growing. About 99 adults with stage IV or inoperable melanoma will be randomly assigned to morning, afternoon,…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Symptom relief
Last updated May 01, 2026 14:17 UTC